Currently, the Group has the following products in the market:
Country of origin |
Market
|
Medical application |
|||
PRC |
Heart & other cardiovascular disease | ||||
PRC |
Vira-infected disease | ||||
PRC |
Shortening bleeding time & reducing loss of blood | ||||
PRC |
Cornea ulcer | ||||
Italy |
Cardiac disease | ||||
Spain |
Sideropenic Anaemias | ||||
France |
Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy | ||||
Italy |
Mucositis induced by chemo radiotherapy | ||||
Italy |
Hypertension | ||||
Italy |
Candiadis | ||||
Italy |
Burns and wounds healing | ||||
Japan |
Gastric Ulcer and Gastritis | ||||
Italy |
PTCA treatment for cardiovascular disease |
Research & development
Market focused development
Expansion through licensing
Building intellectual property portfolio
Clinical development
Established network of opinion leaders in multi-discipline areas
A clinical development team composed of 15 professionals with
4 trained physicians
Local and global trials focus on targeted therapies
Manufacturing
Wholly-owned subsidiary Zhaoke Pharmaceutical (Hefei) Co.,
Ltd located in Hefei, China, comprising 4 GMP-compliantworkshops for the production of topical gel, lyophilized powderfor injection, small volume parenteral solutions and eye gel
Regulatory
5 professionals fully devoted to dossier translation and preparation
More than 25 years of combined experience
Sales & marketing
Extensive network covering every province in the PRC with
600 partnerships covering all of China, including Hong Kong and Macau.
250 strong people direct sales force covering 26 cities in China.
Headquarters in Hong Kong.
Regional offices in Beijing, Shanghai and Guangzhou

